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Objective: Nonsyndromic cleft lip with or without cleft palate (NS-CL/P) are among the most common congenital birth defects worldwide. Several lines of evidence point 
to the involvement of folate, as well as folate metabolizing enzymes in risk reduction of 
orofacial clefts. Dihydrofolate reductase (DHFR) enzyme participates in the metabolic 
cycle of folate and has a crucial role in DNA synthesis, a fundamental feature of gestation 
and development. A functional polymorphic 19-bp deletion within intron-1 of DHFR has 
been associated with the risk of common congenital malformations. The present study 
aimed to evaluate the possible association between DHFR 19-bp deletion polymorphism 
and susceptibility to NS-CL/P in an Iranian population. Material and Methods: The current 
study recruited 100 NS-CL/P patients and 100 healthy controls. DHFR 19-bp deletion was 
determined using an allele specific-PCR method. Results: We observed the DHFR 19-bp 
homozygous deletion genotype (D/D) vs. homozygous wild genotype (WW) was more 
frequent in controls than in NS-CL/P patients (25% vs. 13%), being associated with a 
reduced risk of NS-CL/P in both codominant (OR=0.33, P=0.027) and recessive (OR=0.45, 
P=0.046) tested inheritance models. We also stratified the cleft patients and reanalyzed the 
data. The association trend for CL+CL/P group compared to the controls revealed that the 
DD genotype in both codominant (OR=0.30, P=0.032) and recessive models (OR=0.35, 
P=0.031) was associated with a reduced risk of CL+CL/P. Conclusions: Our results for the 
first time suggested the DHFR 19-bp D/D genotype may confer a reduced risk of NS-CL/P 
and might act as a protective factor against NS-CL/P in the Iranian subjects.
 
Keywords: Dihydrofolate reductase (DHFR). Nonsyndromic cleft lip with or without cleft 
palate (NS-CL/P). Ins/Del polymorphism.
INTRODUCTION
Orofacial clefts (OFC), including cleft lip with 
or without cleft palate (CL/P) and cleft palate only 
or isolated cleft palate (CP), are among the most 
frequent inborn birth defects worldwide20. According 
to their association with special malformative 
patterns or their incidence as isolated defects, 
CL/P can be classified into Syndromic and 
Nonsyndromic (NS-CL/P), respectively. Most CL/P 
cases (approximately 70%) are nonsyndromic, 
although strong genetic factors contribute in both 
forms. Syndromic forms are typically caused by 
chromosomal aberrations or monogenic diseases, 
whereas, NS-CL/P forms result from the interaction 
between genetic and environmental factors. NS-CL/P 
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patients frequently suffer from major complications 
such as difficulties concerning feeding, speech, 
hearing, and psychologic maturation19,21.
Nonsyndromic or isolated (without other 
associated abnormalities) CL/P is a common 
congenitally developmental disorder affecting 1:700 
births worldwide, although this rate is different in 
various ethnic groups and geographic regions19,21. 
Generally, Asian populations have a higher birth 
occurrence of clefting (1/500 births), Caucasians 
are intermediate (1/1,000 births), and African 
populations have the lowest (1/2,500 births). It 
has been reported that the incidence of CL and 
CP in Iran is approximately 1/1,000 lower than 
that in other countries. Clefting is caused by a 
coordinated sequence of events that involve the 
growth of several independently-derived facial 
primordia. Genetic and environmental factors, and 
their interactions, may affect these events and 
contribute to NS-CL/P pathogenesis20.
The development of craniofacial structures is 
the product of social environmental, and nutritional 
factors such as tobacco smoke, alcohol consumption, 
and maternal folic acid deficiency due to exposure 
to folic acid antagonists – such as anticonvulsants26 
– appear to play a role in the development of OFC 
during pregnancy8. Folic acid is a water soluble 
B-vitamin that plays a crucial role in embryonic 
development because it is essential for DNA stability 
maintenance, being involved in DNA synthesis, 
repair, and methylation4,22. Alterations in genes 
responsible for each step of the folate pathway has 
been shown to cause aberrations in organogenesis 
that result in congenital malformations such as 
neural tube defects (NTDs)6 or OFC4. Several lines 
of evidence have confirmed there is a reduced 
risk of OFC and NTDs when mothers used either 
folic acid-containing supplements or dietary folate 
during the periconceptional period. For example, a 
meta-analysis of 11 case-control studies and four 
prospective studies supported the hypothesis that 
taking folic acid-containing supplements during 
pregnancy decreases the risk of NS-CL/P1.
The metabolic cycle of folate is complex, with 
multiple genes participating in the transformation 
of folate into various compounds8. One of these 
genes is dihydrofolate reductase (DHFR), known 
as a strong candidate for a teratogenic locus which 
synthesizes the DHFR enzyme. All of the folate from 
vitamin supplements and food fortification is folic 
acid, a form of folate that is unreduced and requires 
the action of DHFR before it can participate in 
cellular reactions. DHFR converts the dihydrofolate 
(DHF) into tetrahydrofolate (THF) forms that can 
contribute to folate/homocysteine metabolism, and 
subsequent DNA synthesis, a fundamental feature 
in fetal development and organogenesis.
Several gene polymorphisms affect folate 
metabolism and are associated with reduced folate 
absorption and consequently increased folate 
needs. In the absence of a folate-sufficient diet, 
these gene alterations are associated with increased 
risk of NTDs and congenital defects in the offspring4.
The DHFR gene is located at chromosome 
5q11.2-13.2 and is expressed in three mRNA 
isoforms with alternatively spliced 3’UTR ends. The 
changes in DHFR expression or activity can be partly 
due to the functional polymorphisms in the DHFR 
gene, thereby influencing a risk of folate-dependent 
diseases17. A polymorphic 19-bp deletion within 
intron-1 of DHFR has been described; however, 
its biological consequence has been inconsistent. 
Accordingly, the DHFR 19-bp deletion polymorphism 
has been associated with a reduced or increased 
risk of some congenital malformations. For instance, 
the DHFR 19-bp deletion (D)/D genotype in mothers 
has been associated with an increased risk of having 
a baby born with spina bifida (SB)13; whereas 
other studies have suggested the DHFR 19-bp D/D 
genotype is protective against having a baby born 
with SB18 or NTD9,14, verifying the inconsistency 
among different studies.
With respect to the crucial role of folic acid in 
embryonic development, any genetic variations in 
the DHFR gene leading to impaired folate metabolism 
could possibly contribute to predisposition to NS-
CL/P. Therefore, the present study aimed to evaluate 
the possible association between functional 19-bp 
deletion polymorphism within intron-1 of DHFR and 
susceptibility to NS-CL/P in an Iranian population. 
To the best of our knowledge, this is the first study 
examining the possible impact of DHFR 19-bp 
deletion gene variation on NS-CL/P.
MATERIAL AND METHODS
In the current case-control retrospective 
study, a total of 200 subjects – including 100 
CL/P patients (61 male and 39 female) with an 
average age of 12.12 years (Range: 1–54 y) and 
100 normal subjects (61 male and 39 female) 
with an average age of 12.03 years (Range: 1–51 
y) – were involved as previously described by 
this research team19. All samples were collected 
from Zahedan, a South-east Iranian population. 
The control samples were unaffected, unrelated 
individuals without a family history of clefting, 
collected as randomly selected, population-based 
controls from Zahedan. The diagnosis was made 
at the time of birth by physical examination. All 
patients were diagnosed independently and were 
screened to exclude cleft-associated syndromes – 
such as DiGeorge syndrome, Stickler syndrome, 
Nager syndrome, and Van der Woude syndrome – 
by the multidisciplinary team of specialists of each 
center. There was no significant difference between 
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the groups regarding sex and age (P>0.05). All 
participants were unrelated to each other.
The local Ethics Committee of the Zahedan 
University of Medical Sciences approved the project, 
and written informed consent was taken from all 
participants (or their parents). Blood samples from 
all patients and healthy controls were collected in 
EDTA containing tubes and stored at -20°C until 
DNA extraction. Genomic DNA was extracted from 
the peripheral blood leukocytes by the “salting-out” 
method as described previously. The quality of the 
isolated DNA was checked by electrophoresis on 1% 
agarose gel, quantitated spectrophotometrically, 
and stored at -20°C until further use.
Genotyping of the 19-bp deletion of DHFR 
was performed using the allele specific-PCR (AS-
PCR) as described previously by Gemmati, et al.11 
(2009). In the AS-PCR, two different allele-specific 
forward primers (F1 and F2) for the non-deleted 
and deleted polymorphic alleles, respectively, and 
one common reverse primer (R) were applied. To 
verify the accuracy of the method, random samples 
were genotyped by a bi-directional PCR allele-
specific amplification (bi-PASA) PCR as established 
previously by Eskandari-Nasab, et al.8 (2012) and 
Rafighdoost, et al.27 (2013). The bi-PASA included 
two outer primers (FO and RO) and two inner 
allele-specific primers, FI (Insertion allele) and 
RI (Deletion allele), all in one-tube PCR reaction. 
PCR was performed using commercially available 
Prime Taq premix (Genetbio, Chungcheongnam, 
South Korea) according to the manufacturer’s 
recommended protocol. Briefly, 1 µL template DNA 
(~100 ng/µL), 0.7 µL of each primer (10 pmol/mL), 
10 µL Prime Taq premix, and 7 µL DNase-free water 
were added to each PCR tube in a final volume of 
20 µL. Amplification was performed with an initial 
denaturation step at 95°C for 5 min, followed by 
30 cycles at 95°C for 30 s, 60°C for 30 s, and 72°C 
for 25 s with a final extension at 72°C for 10 min. 
Each reaction was verified on a 2% agarose gel. 
The AS-PCR results were 100% concordant with 
the findings of bi-PASA. All primers sequence and 
amplicons size are presented in Figure 1.
Statistical analysis
The statistical analyses of the data were 
performed by the SPSS 18.0 software (SPSS Inc, 
Chicago IL, USA). The associations between alleles 
or genotypes and NS-CL/P were assessed by 
computing the odds ratio (OR) and 95% confidence 
intervals (95% CI) from logistic regression analyses. 
P-values below 0.05 were determined statistically 
significant. Based on our results, sample power was 
analyzed for DHFR polymorphism by comparison 
of each genotype with the accumulation of other 
genotypes by utilizing STATA 10 software.
RESULTS
Of a total of 100 patients, 43 were CL, 26 
were CLP, and 31 were cleft palate only (CP). The 
distribution of genotype and allele frequencies of 
DHFR 19-bp deletion polymorphism is presented 
in Table 1. Our results revealed a statistically 
significant association between DHFR 19-bp deletion 
polymorphism and susceptibility to NS-CL/P in both 
the codominant and recessive tested inheritance 
models. In the codominant model, the DHFR 19-
bp homozygous deletion genotype (D/D), with an 
increased frequency in controls compared to NS-
CL/P patients (25% vs. 13%), was associated with 
a reduced risk of NS-CL/P (D/D vs. W/W genotype; 
OR=0.33, 95% CI=0.32–0.88; P=0.027). Similarly, 
in the recessive model, the DHFR 19-bp D/D 
genotype was associated with susceptibility to 
NS-CL/P and may confer a decreased risk against 
NS-CL/P (D/D vs. W/W+W/D genotype; OR=0.45, 
95% CI=0.20–0.99; P=0.046).
On the other hand, at the allelic level, the DHFR 
19-bp deletion (D) allele was more prevalent in the 
control group compared to the NS-CL/P patients 
(43% vs. 33%), although it was not significantly 
associated with the risk of NS-CL/P (D allele vs. W 
allele; OR=0.68, 95% CI=0.45–1.03, P=0.072).
Table 2 shows the association of DHFR 19-bp 
Primers Sequence (5´ to 3´) Amplicon size
Genotyping Method Bi-PASA PCR
DHFR-FO CTGTCATGGTTGGTTCGCTAAAC 357 bp
DHFR-RO TGGGTAGGGGTGAGGTGTTTTC
DHFR-FI (Del allele) CCACGGTCGGGGTACCTGGG 159 bp
DHFR-RI (Ins allele) GAGTCGGCCACCCCGACCGT 239 bp
Genotyping Method Allele-Specific PCR
DHFR-F1 TCGGGGTACCTGGG 113 bp and
DHFR-F2 ACGGTCGGGGTGGCCGACTC 92 bp
DHFR-R AAAAGGGGAATCCAGTCG
Figure 1- Primers sequence for detection of DHFR 19-bp deletion polymorphism
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polymorphism between the CL+CL/P group and 
the control group. The association trend for the 
CL+CL/P group was almost the same as those for 
all cleft patients: the results demonstrated that DD 
genotype in the codominant model (D/D vs. W/W 
genotype; OR=0.30, 95% CI=0.01–0.90; P=0.032) 
as well as the DD genotype in the recessive model 
(D/D vs. W/W+W/D genotype; OR=0.35, 95% 
CI=0.26–0.86; P=0.031) were associated with a 
reduced risk of CL+CL/P.
DISCUSSION
In the current study, we investigated the impact 
of DHFR 19-bp deletion polymorphism on the risk 
of NS-CL/P. Our results demonstrated that the 
DHFR 19-bp homozygous D/D genotype (in both 
codominant and recessive models) was associated 
with a reduced risk of NS-CL/P. The results indicated 
that individuals carrying the DHFR 19-bp D/D 
genotype in the codominant and recessive models 
had, respectively, a 0.33- and a 0.45-fold reduced 
Genotypes CL+CL/P n (%) Controls n (%) OR (95%CI) P-value Study Power %
DHFR, 19-bp deletion polymorphism
Codominant
W/W 13 (18.8) 12 (12) Reference - 18
W/D 48 (69.6) 63 (63) 0.70 (0.30-1.68) 0.428 11
D/D 8 (11.6) 25 (25) 0.30 (0.01-0.90) 0.032 50
Dominant
W/W 13 (18.8) 12 (12) Reference - 18
W/D+D/D 56 (81.2) 88 (88) 0.59 (0.23-1.49) 0.271 18
Recessive
W/W+W/D 61 (88.4) 75 (75) Reference - 50
D/D 8 (11.6) 25 (25) 0.35 (0.26-0.86) 0.031 50
Alleles
W 74 (54) 87 (44) Reference - 40
D 64 (46) 113 (56) 0.66 (0.41-1.08) 0.067 40
Table 2- Genotype and allele frequencies of DHFR 19-bp deletion polymorphism between patients with nonsyndromic cleft 
patients without CP  and control subjects
(CL/P)=cleft lip with or without cleft palate
Genotypes NS-CL/P Patients n (%) Controls n (%) OR (95%CI) P-value Study Power %
DHFR, 19-bp deletion polymorphism
Codominant
W/W 19 (19) 12 (12) Reference - 22
W/D 68 (68) 63 (63) 0.68 (0.31-1.52) 0.348 9
D/D 13 (13) 25 (25) 0.33 (0.32-0.88) 0.027 51
Dominant
W/W 19 (19) 12 (12) Reference - 22
W/D+D/D 81 (81) 88 (88) 0.58 (0.25-1.36) 0.241 22
Recessive
W/W+W/D 87 (87) 75 (75) Reference - 51
D/D 13 (13) 25 (25) 0.45 (0.20-0.99) 0.046 51
Alleles
W 106 (53) 87 (44) Reference - 40
D 94 (47) 113 (56) 0.68 (0.45-1.03) 0.072 40
Table 1- Genotype and allele frequencies of DHFR 19-bp deletion polymorphism between patients with nonsyndromic cleft 
lip and/or cleft palate (NS-CL/P) and control subjects
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risk of developing NS-CL/P compared to those 
carrying the W/W genotype. We also stratified the 
cleft patients according to their etiology into CP and 
CL+CL/P patients, and evaluated the association of 
DHFR 19-bp deletion polymorphism and the risk 
of CL+CL/P by comparing with the controls. The 
results demonstrated that the DD genotype in both 
codominant and recessive models was associated 
with a reduced risk of CL+CL/P. Thus, our findings 
highlight the protective role of DHFR 19-bp deletion 
polymorphism against susceptibility to NS-CL/P 
in our population. Similarly, Parle-McDermott, et 
al.18 (2007) have shown a significantly lower risk 
of having a child with NTDs in women with the D/D 
or W/D genotypes than in women with the W/W 
genotype, suggesting that the 19-bp D allele may 
be a protective NTD genetic factor. However, other 
studies13,17 have shown that the DHFR 19-bp D/D 
genotype vs. W/W genotype increased the risk of 
having a child with unilateral retinoblastoma or SB.
The polymorphic 19-bp deletion within intron-1 
of DHFR appears to play important roles in 
the transcription of DHFR and the quantity of 
protein produced by translation. However, the 
precise consequence of the DHFR 19-bp deletion 
polymorphism has been controversial. Firstly, 
Johnson, et al.13 (2004) suggested the D allele 
might decrease the DHFR expression, since the 
Sp1 transcription factor binding site is located 
within the deleted sequence. They suggested the 
homozygous D/D genotype in mothers is related to 
an increased risk of preterm delivery12 or having a 
baby born with SB13. However, Parle-McDermott, 
et al.18 (2007) in a larger study have shown that 
the D/D genotype is protective and decreases the 
risk of having a baby born with SB. Additionally, 
they18 reported that DHFR mRNA expression was 
50% higher in lymphoblast cell lines with the D/D 
genotype than in cell lines with the W/W genotype. 
Moreover, Xu, et al.28 (2007) observed a dose-
dependent relation between DHFR expression and 
the D/D genotype, proposing that subjects with the 
D/D genotype express 4.8-fold more DHFR mRNA 
levels compared to subjects carrying the 19-bp 
W/W genotype. Stanislawska-Sachadyn, et al.23 
(2008) also reported that individuals with the D/D 
genotype have increased serum and red blood cell 
folate levels and lower homocysteine levels. These 
findings were confirmed by others10,25, who showed 
a significant decrease in plasma homocysteine 
concentration for the DHFR D/D genotype relative 
to the W/W genotype. This would affirm the possible 
maternal protective role of the 19-bp deletion allele 
in NS-CL/P by increasing the amount of DHFR 
available to reduce DHF to THF, and by augmenting 
bioavailability of folate cofactors required for a 
number of cellular reactions in pregnant women. 
However, any potential functional effect of the 19-bp 
deletion needs to be examined further in the context 
of the cell cycle and/or under low folate conditions. 
Martinelli, et al.20 (2014) also examined four SNPs 
of DHFR gene on cleft patients, and their study is 
different from ours in the way that we examined 
the 19-bp Ins/Del polymorphism of DHFR in cleft 
patients.
Multiple studies have demonstrated strong 
evidence for the contribution of Interferon 
regulatory factor 6 (IRF6) signalling pathway to 
the risk of nonsyndromic oral clefts across various 
ethnic groups. The IRF6 from chromosomal region 
1q32.2 has previously been shown to account 
for the majority of patients with Van der Woude 
syndrome (VWS), the most common Mendelian 
deformity syndrome which includes oral clefts as a 
hallmark feature. Several genetic markers in IRF6 
have provided evidence of linkage and linkage 
disequilibrium (LD) in studies of nonsyndromic oral 
clefts and have been associated with CL/P in many 
populations5,24,30.
Variations in WNT (wingless-type MMTV 
integration site family) genes have also been 
associated with human nonsyndromic oral clefts. 
WNT signalling performs as an up-regulator of p63 
and interferon regulatory factor 6 (IRF6), which 
regulates precise facial process fusion by controlling 
epithelial cell proliferation and differentiation. 
Variants within WNT genes were shown to contribute 
to cleft lip and palate, and mutations in WNT3 
underlie autosomal-recessive tetra-amelia with cleft 
lip and palate. In family-based studies, a variety of 
WNT genes (WNT3A, WNT5A, WNT8A, and WNT11) 
have been shown to have an association with cleft 
lip/palate. Furthermore, studies in animal models 
have revealed the crucial role of WNTs family in 
craniofacial development. WNT3 and WNT9B are 
located in the cleft loci 1 (clf1) and could contribute 
to the clefting phenotype15. Targeted mutation in 
the mouse WNT9B gene resulted in an incomplete 
penetrance of CLP, suggesting the importance of 
WNTs in the pathogenesis of orofacial clefts3,16.
A number of other genes have also been 
implicated in NS-CL/P pathogenesis including 
transforming growth factor-alpha (TGFA), bone 
morphogenetic proteins (Bmp), fibroblast growth 
factors (Fgf), and members of the transforming 
growth factor b (TGFB) superfamily. Mutations 
in TGFA, msh homeobox 1 (MSX1), fibroblast 
growth factor receptor 1 (FGFR1) and FGF8, 
and bone morphogenetic protein 4 (BMP4) have 
also been demonstrated to underlie the NS-CL/
P7. The presence of TGFA in the regulation of 
palate development and its high levels in medial 
edge epithelia (MEE) of palatal shelves have 
been demonstrated29. Bmp2 and Bmp4 are 
expressed more specifically within the epithelia 
and mesenchyme of the palatal shelves. The 
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Msx1 homeobox gene, which is also expressed in 
the facial primordia, is needed for expression of 
Bmp2 and Bmp4 in the palatal mesenchyme. In 
addition, epidermal growth factor (EGF) stimulates 
glycosaminoglycan production within the palatal 
shelves7,29.
Orofacial development is a quite harmonized 
process of cell proliferation, differentiation, 
migration, and apoptosis. The quick growth and the 
consecutive fusion of maxillary processes and palatal 
shelves during early embryogenesis are crucial 
stages in orofacial development, both requiring an 
effective methyl synthesis and availability21. DHFR 
is also needed for the intracellular conversion of 
synthetic folic acid, consumed in supplements 
and fortified foods, into the THF forms that can 
contribute to folate/homocysteine metabolism. 
Defective DHFR activity has been associated with a 
rapid depletion of THF pool within the cell affecting 
the level of folate coenzymes and hence purine and 
pyrimidine synthesis, and consequent termination 
of de-novo DNA synthesis and histone methylation, 
that are all essential for cell proliferation and 
regulation of gene expression during embryonic 
development10. The use of folic acid supplementation 
during pregnancy in protection against congenital 
malformations such as OFCs2, NTD4, and SB27 has 
been supported by several studies. These studies 
support the protective role of folic acid intake during 
the pre-, peri-, and postconceptional periods on 
the risk of OFCs8, suggesting that the occurrence 
of OFCs can be reduced with prophylactic use of 
folate by women in the periconceptional period. 
Two hypotheses may explain the harmful effects 
of low folate levels during pregnancy.
One of the limitations of our study is the 
relatively small sample size. Therefore, the results 
should be interpreted with caution. Furthermore, 
our study deviated somehow from HWE (Hardy 
Weinberg Equilibrium). There is no clear explanation 
for the deviation from HWE in our population. 
However, the small sample size, consanguineous 
marriages, or genetic drift could be possible reasons 
in this population.
CONCLUSIONS
Our data suggests that DHFR 19-bp D/D 
genotype is associated with a reduced risk of NS-
CL/P in both the codominant and recessive models. 
This finding highlights the protective role of DHFR 
19-bp deletion polymorphism against susceptibility 
to NS-CL/P in an Iranian population. Future research 
with larger samples from different ethnicities is 
required to validate our findings.
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